title: Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.
abstract: MicroRNAs (miRNAs) are involved in cancer pathogenesis, apoptosis, and cell growth, and these miRNAs are thought to be functional as oncogenes and/or tumor suppressors in the gene regulatory networks. We studied the potential contribution of miRNAs in acute promyelocytic leukemia (APL) cell NB4 during the apoptosis induction by arsenic trioxide (ATO). The apoptotic effects of ATO on the NB4 cell line at a pharmacological dose (2 μM) was verified using cell growth and viability assays, MTT assay, BrdU cell proliferation assay, flow cytometric analysis, and caspase-3 activity assay. miRNAs from untreated and 2 μM ATO-treated NB4 cell line were extracted, purified, and converted to complementary DNAs. Differential expressions of 88 cancer-related miRNAs were analyzed by real-time reverse transcription PCR using miRNA PCR cancer-array system. After normalizing to the average Ct value of three housekeeping genes in the array (U6, SNORD47, and SNORD48), the fold change of miRNAs was calculated in the ATO-treated cells as compared to untreated. Among the 88 cancer-focused miRNAs, 51 miRNAs were found to be differentially expressed more than 2-fold after ATO treatment. Of these, 48 miRNAs were upregulated up to 21.65-fold changes, while three miRNAs were downregulated up to 5.19-fold changes. By screening the literature, a majority of these upregulated miRNAs were found to have tumor and/or metastatic suppressors' functions associated with cell cycle arrest and apoptosis, as well as inhibition of angiogenesis, invasion, and metastasis. Our results demonstrate that ATO, at the relevant concentration, modulate a substantial number of cancer-related miRNAs in APL cell line; most of these are known to function as a tumor and/or metastatic suppressors and have confirmed targets involved in cell cycle arrest and apoptosis. The results of this study support the hypothesis that miRNAs may play a mediatory role in eliciting the multi-target and pleiotropic action of ATO.
authors.affiliation: Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. shghaffari200@yahoo.com
authors.forename: Seyed H
authors.initials: SH
authors.lastname: Ghaffari
authors.forename: Davood
authors.initials: D
authors.lastname: Bashash
authors.forename: Majid Zaki
authors.initials: MZ
authors.lastname: Dizaji
authors.forename: Ardeshir
authors.initials: A
authors.lastname: Ghavamzadeh
authors.forename: Kamran
authors.initials: K
authors.lastname: Alimoghaddam
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D015870:Gene Expression / Q000187:drug effects*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics* / Q000473:pathology; D035683:MicroRNAs / Q000235:genetics*; D010087:Oxides / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D035683:MicroRNAs; D010087:Oxides; D000077237:Arsenic Trioxide
references.citation: FEBS J. 2009 Nov;276(22):6689-700
references.pmid: 19843160
references.citation: Int J Cancer. 2010 May 1;126(9):2036-48
references.pmid: 19739117
references.citation: Cancer Res. 2008 Apr 1;68(7):2094-105
references.pmid: 18381414
references.citation: Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15535-40
references.pmid: 18832181
references.citation: Oncogene. 2008 Sep 18;27(42):5643-7
references.pmid: 18504431
references.citation: Cancer Res. 2010 Jul 15;70(14):6015-25
references.pmid: 20610624
references.citation: Biochim Biophys Acta. 2010 Apr;1805(2):209-17
references.pmid: 19931352
references.citation: Lung Cancer. 2009 Nov;66(2):169-75
references.pmid: 19223090
references.citation: Oncogene. 2007 Jun 14;26(28):4148-57
references.pmid: 17260024
references.citation: Nucleic Acids Res. 2009 Jan;37(Database issue):D105-10
references.pmid: 18996891
references.citation: Int J Cancer. 2010 Sep 1;127(6):1363-72
references.pmid: 20073067
references.citation: Int J Cancer. 2001 Jan 15;91(2):173-9
references.pmid: 11146441
references.citation: Mutat Res. 2011 Jun 17;722(2):94-105
references.pmid: 20472093
references.citation: Cancer Res. 2009 Jul 1;69(13):5553-9
references.pmid: 19549910
references.citation: J Biol Chem. 2008 Nov 28;283(48):33394-405
references.pmid: 18818206
references.citation: Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
references.pmid: 16166262
references.citation: Cancer Res. 2009 Jul 15;69(14):5761-7
references.pmid: 19584283
references.citation: Am J Pathol. 2009 Apr;174(4):1131-8
references.pmid: 19264914
references.citation: Cell. 2006 Mar 24;124(6):1169-81
references.pmid: 16564011
references.citation: Mol Cancer. 2010 Apr 30;9:96
references.pmid: 20433742
references.citation: Dev Biol. 2007 Feb 1;302(1):1-12
references.pmid: 16989803
references.citation: Mol Cells. 2009 Dec 31;28(6):521-7
references.pmid: 19937137
references.citation: Biochem Biophys Res Commun. 2010 Jan 15;391(3):1483-9
references.pmid: 20034472
references.citation: Cancer Lett. 2010 Dec 1;298(1):50-63
references.pmid: 20619534
references.citation: Blood. 2008 Mar 15;111(6):3183-9
references.pmid: 18187662
references.citation: Carcinogenesis. 2008 Sep;29(9):1831-6
references.pmid: 18321869
references.citation: Cancer. 2010 Jan 1;116(1):41-9
references.pmid: 19890957
references.citation: Philos Trans R Soc Lond B Biol Sci. 2007 Jun 29;362(1482):959-71
references.pmid: 17317642
references.citation: Int J Cancer. 2009 Sep 15;125(6):1407-13
references.pmid: 19536818
references.citation: Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8
references.pmid: 16039986
references.citation: Blood. 1997 May 1;89(9):3354-60
references.pmid: 9129042
references.citation: BMC Cancer. 2010 Jun 22;10:318
references.pmid: 20569443
references.citation: Br J Cancer. 2009 Aug 18;101(4):699-706
references.pmid: 19638978
references.citation: PLoS One. 2008 May 14;3(5):e2141
references.pmid: 18478077
references.citation: PLoS Genet. 2010 Mar 12;6(3):e1000879
references.pmid: 20300657
references.citation: FEBS Lett. 2008 Oct 29;582(25-26):3663-8
references.pmid: 18840437
references.citation: Clin Exp Pharmacol Physiol. 2009 Oct;36(10):951-60
references.pmid: 19566826
references.citation: Blood. 2005 Feb 1;105(3):1237-45
references.pmid: 15466933
references.citation: Leuk Res. 2009 Nov;33(11):1530-8
references.pmid: 19464056
references.citation: J Clin Oncol. 2010 Aug 20;28(24):3866-71
references.pmid: 20644086
references.citation: Cancer Res. 2008 Dec 15;68(24):10094-104
references.pmid: 19074875
references.citation: Exp Mol Med. 2009 Dec 31;41(12):912-8
references.pmid: 19745602
references.citation: Ann Oncol. 2006 Oct;17(10):1553-9
references.pmid: 16831853
references.citation: Cancer Invest. 2010 Dec;28(10):1024-30
references.pmid: 20874002
references.citation: Med Oncol. 2010 Sep;27(3):833-42
references.pmid: 19763917
references.citation: Eur J Cancer. 2010 Jan;46(2):298-311
references.pmid: 19948396
references.citation: J Hepatol. 2010 May;52(5):698-704
references.pmid: 20347499
references.citation: Cancer Res. 2002 Jul 15;62(14):3893-903
references.pmid: 12124315
references.citation: Int J Cancer. 2011 May 15;128(10):2274-83
references.pmid: 20658525
references.citation: J Cell Physiol. 2010 May;223(2):289-98
references.pmid: 20112282
references.citation: Science. 2010 Apr 9;328(5975):240-3
references.pmid: 20378816
references.citation: Stem Cell Rev. 2005;1(3):197-205
references.pmid: 17142856
references.citation: Exp Cell Res. 2006 Dec 10;312(20):4120-38
references.pmid: 17070520
references.citation: Hum Pathol. 2006 Mar;37(3):298-311
references.pmid: 16613325
references.citation: Cancer Lett. 2009 Nov 1;284(2):208-15
references.pmid: 19457607
references.citation: Biochem Biophys Res Commun. 2010 Feb 12;392(3):340-5
references.pmid: 20067763
references.citation: Best Pract Res Clin Haematol. 2009 Jun;22(2):239-48
references.pmid: 19698931
references.citation: Biol Trace Elem Res. 2010 Sep;136(3):294-301
references.pmid: 19838642
references.citation: FEBS J. 2009 Oct;276(19):5571-8
references.pmid: 19702827
references.citation: Bioinformatics. 2009 Aug 1;25(15):1991-3
references.pmid: 19435746
references.citation: Nature. 2008 Jan 10;451(7175):147-52
references.pmid: 18185580
references.citation: Leuk Lymphoma. 2008 Oct;49(10):1846-51
references.pmid: 18949607
references.citation: Cancer Cell. 2010 Feb 17;17(2):173-85
references.pmid: 20159609
references.citation: Nat Rev Cancer. 2010 Nov;10(11):775-83
references.pmid: 20966922
references.citation: Curr Med Chem. 2008;15(22):2293-304
references.pmid: 18781951
references.citation: Blood. 2009 Aug 6;114(6):1150-7
references.pmid: 19401558
references.citation: J Biol Chem. 2010 Mar 12;285(11):7986-94
references.pmid: 20075075
references.citation: Int J Cancer. 2010 Dec 1;127(11):2520-9
references.pmid: 20162574
references.citation: Ann Oncol. 2006 Jan;17(1):131-4
references.pmid: 16227315
references.citation: Int J Cancer. 2011 Apr 15;128(8):1758-69
references.pmid: 20549700
references.citation: Blood. 2009 Jan 8;113(2):412-21
references.pmid: 18941112